%0 Review
%T Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.
%A Martin P
%A Awan AA
%A Berenguer MC
%A Bruchfeld A
%A Fabrizi F
%A Goldberg DS
%A Jia J
%A Kamar N
%A Mohamed R
%A Pessôa MG
%A Pol S
%A Sise ME
%A Balk EM
%A Gordon CE
%A Adam G
%A Cheung M
%A Earley A
%A Jadoul M
%J Kidney Int
%V 102
%N 6
%D 12 2022
%M 36411019
%F 18.998
%R 10.1016/j.kint.2022.07.012
%X Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy or with a kidney transplant. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2018, advances in HCV management, particularly in the field of antiviral therapy and treatment of HCV-associated glomerular diseases, coupled with increased usage of HCV-positive kidney grafts, have prompted a reexamination of the 2018 guideline. As a result, the Work Group performed a comprehensive review and revised the 2018 guidance. This Executive Summary highlights key aspects of the updated guideline recommendations for 3 chapters: Chapter 2: Treatment of HCV infection in patients with CKD; Chapter 4: Management of HCV-infected patients before and after kidney transplantation; and Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection.